Jump to content

TROPION-Lung05 Study


Recommended Posts


TROPION-Lung05 Study.

Daiichi Sankyo, Inc. has begun a study of an investigational drug called DS-1062a for adults with NSCLC. The goal of the study is to evaluate DS-1062a to find out how well it works to slow tumor growth in patients with advanced or metastatic NSCLC.

You may pre-qualify for the TROPION-Lung05 Study if you:

- Are at least 18 years of age

- Have been diagnosed with advanced or metastatic (Stage IIIB, IIIC or IV) NSCLC

- Have received certain types of previous anti-cancer treatment (the study team can help confirm if your previous treatment meets study requirements)

You will receive study-related care throughout the study from a team of experienced physicians and a dedicated study team.

Study Procedures

• The study is divided into 3 periods: Screening Period, Treatment Period, and Follow-up Period.

ClinicalTrials.gov Identifier: NCT04484142

For more information, please contact Lan Lan llan@dsi.com, 609-208-4597


Add to Your Post



Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.